SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA): Italian Network for the Study of CAA

What this Trial Is About

Researchers are investigating cerebral amyloid angiopathy (CAA), a major type of small vessel disease in the brain that can cause spontaneous brain bleeding and cognitive decline in older adults. This study aims to better understand the disease's natural history, clinical signs, brain imaging features, and progression by collecting detailed patient data. The SENECA project is Italy's first multicenter cohort study focused on improving diagnosis and knowledge of CAA through a multidisciplinary approach. The study collects demographic, clinical, and neuroradiological data from patients diagnosed with possible, probable, or definite CAA, including both symptomatic and asymptomatic cases. Participants must have had at least one brain MRI. Neurologists gather information on patient history, symptoms, vascular risks, family history, and treatments. This observational study involves a network of specialists working together to standardize data collection and build a large biorepository of CAA patients. Participants will undergo clinical and neuroradiological evaluations over 24 months to monitor disease characteristics and severity. Data collection includes brain imaging and clinical records to identify markers of disease progression. The study monitors patients without administering treatments, focusing on understanding CAA's course to inform future clinical guidelines. The total observation period for each participant is at least two years, with ongoing assessments during this time.

SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)